S
Shakti D. Shukla
Researcher at University of Newcastle
Publications - 80
Citations - 2641
Shakti D. Shukla is an academic researcher from University of Newcastle. The author has contributed to research in topics: COPD & Medicine. The author has an hindex of 24, co-authored 70 publications receiving 1586 citations. Previous affiliations of Shakti D. Shukla include University of Tasmania.
Papers
More filters
Journal ArticleDOI
The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress
Kamal Dua,Kamal Dua,Kamal Dua,Ridhima Wadhwa,Gautam Singhvi,Vamshikrishna Rapalli,Shakti D. Shukla,Madhur D. Shastri,Gaurav Gupta,Saurabh Satija,Meenu Mehta,Navneet Khurana,Rajendra Awasthi,Pawan Kumar Maurya,Lakshmi Thangavelu,Shanmugam Rajeshkumar,Murtaza M. Tambuwala,Trudi Collet,Philip M. Hansbro,Philip M. Hansbro,Philip M. Hansbro,Dinesh Kumar Chellappan +21 more
TL;DR: The different siRNA nanocarrier systems for chronic respiratory diseases, for safe and effective delivery are discussed, and siRNA mediated pro‐inflammatory gene or miRNA targeting approach can be a useful approach in combating chronic respiratory inflammatory conditions.
Journal ArticleDOI
Functional effects of the microbiota in chronic respiratory disease.
Kurtis F. Budden,Shakti D. Shukla,Saima Firdous Rehman,Kate L Bowerman,Simon Keely,Philip Hugenholtz,Darius Armstrong-James,Ian M. Adcock,Sanjay H. Chotirmall,Kian Fan Chung,Philip M. Hansbro,Philip M. Hansbro +11 more
TL;DR: Recent advances in the understanding of the composition of the lung microbiome, including the virome and mycobiome, the mechanisms by which these microbes interact with host immunity, and their functional effects on the pathogenesis, exacerbations, and comorbidities of chronic respiratory diseases are reviewed.
Journal ArticleDOI
Microbiome effects on immunity, health and disease in the lung.
TL;DR: How microbiota may mediate the dynamic process of immune development and/or regulation furthers the understanding of the pathogenesis of chronic pulmonary diseases and may yield novel avenues for the utilisation of microbiota as potential therapeutic interventions.
Journal ArticleDOI
Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease.
Kate L Bowerman,Saima Firdous Rehman,Annalicia Vaughan,Nancy Lachner,Kurtis F. Budden,Richard Kim,David L. A. Wood,Shaan L. Gellatly,Shakti D. Shukla,Lisa Wood,Ian A. Yang,Peter A. B. Wark,Philip Hugenholtz,Philip M. Hansbro,Philip M. Hansbro +14 more
TL;DR: The results suggest that the faecal microbiome and metabolome of COPD patients are distinct from those of healthy individuals, and may thus aid in the search for biomarkers for COPD.
Journal ArticleDOI
Role of Oxidative Stress in the Pathology and Management of Human Tuberculosis
Shastri,Shakti D. Shukla,Wai Chin Chong,Kamal Dua,Gregory M. Peterson,Rahul P. Patel,Philip M. Hansbro,Rajaraman Eri,Ronan F. O’Toole +8 more
TL;DR: In this paper, the authors review the interplay between lung oxidative stress and its effects on both activation of antitubercle antibiotics and the strategies employed by M. tuberculosis to counter the host's OS response.